Skip to main content

Table 4 Compliance to adjuvant chemotherapy

From: Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer

  No. of patients (%)
Cycle of DCS
 1 29 (96.7)
 2 25 (83.3)
S-1 administration period (month)
 3 28 (93.3)
 6 27 (90.0)
 9 23 (76.7)
 12 18 (60.0)